TD Cowen Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

February 28, 2025 3:06 PM

TD Cowen analyst Phil Nadeau reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found